Mutational inactivation of STAG2 causes aneuploidy in human cancer
- David A. Solomon,
- Taeyeon Kim,
- ,
- Joshlean Fair,
- Abdel G. Elkahloun,
- Brent T. Harris
- Georgetown University School of Medicine,
- UT-Southwestern Medical Center,
- National Human Genome Research Institute (NHGRI),
- National Cancer Institute (NCI),
- Memorial Sloan-Kettering Cancer Center,
- University of California at San Francisco
Publication metrics
PlumX, opens in new tab
Abstract
Most cancer cells are characterized by aneuploidy, an abnormal number of chromosomes. We have identified a clue to the mechanistic origins of aneuploidy through integrative genomic analyses of human tumors. A diverse range of tumor types were found to harbor deletions or inactivating mutations of STAG2, a gene encoding a subunit of the cohesin complex, which regulates the separation of sister chromatids during cell division. Because STAG2 is on the X chromosome, its inactivation requires only a single mutational event. Studying a near-diploid human cell line with a stable karyotype, we found that targeted inactivation of STAG2 led to chromatid cohesion defects and aneuploidy, whereas in two aneuploid human glioblastoma cell lines, targeted correction of the endogenous mutant alleles of STAG2 led to enhanced chromosomal stability. Thus, genetic disruption of cohesin is a cause of aneuploidy in human cancer.
Sustainable Development Goals
- SDG 3 Good Health and Well
Bibliographic Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 1039-1043 (5 pages)Journal (Volume, Issue Number)
Science (Volume 333, Issue 6045)Publication milestones
- Published - 19/08/2011
Publication status
ISSN
0036-8075Publication IDs
- Scopus: 80051874823
- PubMed: 21852505
